Endometriumkarzinom – ein Update

Organization WH (2020) GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020. https://gco.iarc.fr/today/data/factsheets/cancers/24-Corpus-uteri-fact-sheet.pdf. Zugegriffen: 17. Juni 2022 Zhang S, Gong TT, Liu FH, Jiang YT, Sun H, Ma XX et al (2019) Global, regional, and national burden of endometrial cancer, 1990–2017: results from the global burden of disease study, 2017. Front Oncol 9:1440 Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387(10023):1094–1108 Koskas M, Amant F, Mirza MR, Creutzberg CL (2021) Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet 155(Suppl 1):45–60 Ramon-Patino JL, Ruz-Caracuel I, Heredia-Soto V, Garcia de la Calle LE, Zagidullin B, Wang Y et al (2022) Prognosis stratification tools in early-stage endometrial cancer: could we improve their accuracy? Cancers (basel) 14(4):912. https://doi.org/10.3390/cancers14040912 Institute NC (2015) Endometrial cancer treatment physician data query (PDQ). https://www.cancer.gov/types/uterine/hp/endometrial-treatment-pdq. Zugegriffen: 17. Juni 2022 American College of Obstetricians and Gynecologists (2005) ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 106(2):413–425 Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA (2006) Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 19(8):1091–1100 Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123(5):802–813 Ali A, Black D, Soslow RA (2007) Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 26(2):115–123 Köbel M, Nelson GS (2018) Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538–549. J Pathol 245(2):249–250 Alexa M, Hasenburg A, Battista MJ (2021) The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers (basel) 13(6):1478. https://doi.org/10.3390/cancers13061478 Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39 Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R et al (2017) Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 317(12):1224–1233 Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS et al (2012) Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30(7):695–700 Kaban A, Topuz S, Erdem B, Sozen H, Numanoğlu C, Salihoğlu Y (2018) Is Omentectomy necessary for non-endometrioid endometrial cancer. Gynecol Obstet Invest 83(5):482–486 Dutta SW, Trifiletti DM, Grover S, Boimel P, Showalter TN (2017) Management of elderly patients with early-stage medically inoperable endometrial cancer: systematic review and national cancer database analysis. Brachytherapy 16(3):526–533 Burg LC, Hengeveld EM, ’t Hout IJ, Bulten J, Bult P, Zusterzeel PLM (2021) Ultrastaging methods of sentinel lymph nodes in endometrial cancer—a systematic review. Int J Gynecol Cancer 31(5):744–753 Bogani G, Mariani A, Paolini B, Ditto A, Raspagliesi F (2019) Low-volume disease in endometrial cancer: the role of micrometastasis and isolated tumor cells. Gynecol Oncol 153(3):670–675 León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A et al (2020) Molecular classification of the PORTEC‑3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38(29):3388–3397 van den Heerik A, Horeweg N, Nout RA, Lutgens L, van der Steen-Banasik EM, Westerveld GH et al (2020) PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 30(12):2002–2007 Nasioudis D, Roy AG, Ko EM, Cory L, Giuntoli Ii RL, Haggerty AF et al (2020) Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium. Int J Gynecol Cancer 30(8):1089–1094 Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA et al (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105(15):1142–1150 Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS et al (2020) Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209). J Clin Oncol 38(33):3841–3850 Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL et al (2020) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 38(26):2981–2992 Gu H, Li J, Gu Y, Tu H, Zhou Y, Liu J (2017) Survival impact of ovarian preservation on women with early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 27(1):77–84 Garzon S, Uccella S, Zorzato PC, Bosco M, Franchi MP, Student V et al (2021) Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med 112(1):55–69